Biohaven Ltd. Announces Pivotal Trials for Groundbreaking MoDE™ and TRAP™ Degraders Targeting Graves' Disease and IgA Nephropathy

Reuters

05-29

Biohaven Ltd. Announces Pivotal Trials for Groundbreaking MoDE™ and TRAP™ Degraders Targeting Graves' Disease and IgA Nephropathy

NEW HAVEN, Conn., May 28, 2025 - Biohaven Ltd. $(BHVN)$, a clinical-stage biopharmaceutical company, has announced plans to initiate pivotal trials for their drug candidates in the treatment of Graves' Disease and IgA nephropathy. The trials are set to begin in the second half of 2025 and the first half of 2026, respectively. During their recent R&D Day, Biohaven highlighted the success of their MoDE™ and TRAP™ degraders, specifically BHV-1300 and BHV-1400, which have shown significant selectivity and efficacy in early studies. BHV-1400, designed for IgA nephropathy, has achieved over 80% sustained reductions in galactose-deficient IgA1 levels, demonstrating potential as a first-in-class treatment. The drug was well-tolerated in Phase 1 trials, with most adverse events reported as mild and self-resolving. Biohaven's focus remains on advancing precision therapies for immune-mediated diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE97891) on May 28, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2539405200"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539405200\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2539405200?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-29 03:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539405200","market":"nz","top_or_hot":-1,"title":"Biohaven Ltd. Announces Pivotal Trials for Groundbreaking MoDE™ and TRAP™ Degraders Targeting Graves' Disease and IgA Nephropathy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Biohaven Ltd. Announces Pivotal Trials for Groundbreaking MoDE™ and TRAP™ Degraders Targeting Graves' Disease and IgA Nephropathy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NEW HAVEN, Conn., May 28, 2025 - Biohaven Ltd. <a href=\"https://laohu8.com/S/BHVN\">$(BHVN)$</a>, a clinical-stage biopharmaceutical company, has announced plans to initiate pivotal trials for their drug candidates in the treatment of Graves' Disease and IgA nephropathy. The trials are set to begin in the second half of 2025 and the first half of 2026, respectively. During their recent R&amp;D Day, Biohaven highlighted the success of their MoDE™ and TRAP™ degraders, specifically BHV-1300 and BHV-1400, which have shown significant selectivity and efficacy in early studies. BHV-1400, designed for IgA nephropathy, has achieved over 80% sustained reductions in galactose-deficient IgA1 levels, demonstrating potential as a first-in-class treatment. The drug was well-tolerated in Phase 1 trials, with most adverse events reported as mild and self-resolving. Biohaven's focus remains on advancing precision therapies for immune-mediated diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE97891) on May 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven Ltd. Announces Pivotal Trials for Groundbreaking MoDE™ and TRAP™ Degraders Targeting Graves' Disease and IgA Nephropathy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven Ltd. Announces Pivotal Trials for Groundbreaking MoDE™ and TRAP™ Degraders Targeting Graves' Disease and IgA Nephropathy\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-29 03:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Biohaven Ltd. Announces Pivotal Trials for Groundbreaking MoDE™ and TRAP™ Degraders Targeting Graves' Disease and IgA Nephropathy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NEW HAVEN, Conn., May 28, 2025 - Biohaven Ltd. <a href=\"https://laohu8.com/S/BHVN\">$(BHVN)$</a>, a clinical-stage biopharmaceutical company, has announced plans to initiate pivotal trials for their drug candidates in the treatment of Graves' Disease and IgA nephropathy. The trials are set to begin in the second half of 2025 and the first half of 2026, respectively. During their recent R&amp;D Day, Biohaven highlighted the success of their MoDE™ and TRAP™ degraders, specifically BHV-1300 and BHV-1400, which have shown significant selectivity and efficacy in early studies. BHV-1400, designed for IgA nephropathy, has achieved over 80% sustained reductions in galactose-deficient IgA1 levels, demonstrating potential as a first-in-class treatment. The drug was well-tolerated in Phase 1 trials, with most adverse events reported as mild and self-resolving. Biohaven's focus remains on advancing precision therapies for immune-mediated diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE97891) on May 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL9rQ4vT:1","article_id":"2539405200","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539405200","pubTimestamp":1748458826,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biohaven Ltd. Announces Pivotal Trials for Groundbreaking MoDE and TRAP Degraders Targeting Graves' Disease and IgA Nephropathy. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire  on May 28, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Biohaven Ltd.宣布针对格雷夫斯病和IgA肾病的突破性模式™和陷阱™降解剂的关键试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHVN":0.9},"content_text":"Biohaven Ltd. Announces Pivotal Trials for Groundbreaking MoDE™ and TRAP™ Degraders Targeting Graves' Disease and IgA Nephropathy\n    \n\n        NEW HAVEN, Conn., May 28, 2025 - Biohaven Ltd. $(BHVN)$, a clinical-stage biopharmaceutical company, has announced plans to initiate pivotal trials for their drug candidates in the treatment of Graves' Disease and IgA nephropathy. The trials are set to begin in the second half of 2025 and the first half of 2026, respectively. During their recent R&D Day, Biohaven highlighted the success of their MoDE™ and TRAP™ degraders, specifically BHV-1300 and BHV-1400, which have shown significant selectivity and efficacy in early studies. BHV-1400, designed for IgA nephropathy, has achieved over 80% sustained reductions in galactose-deficient IgA1 levels, demonstrating potential as a first-in-class treatment. The drug was well-tolerated in Phase 1 trials, with most adverse events reported as mild and self-resolving. Biohaven's focus remains on advancing precision therapies for immune-mediated diseases.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE97891) on May 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}